{
    "nct_id": "NCT06054555",
    "official_title": "A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma",
    "inclusion_criteria": "* At least 18 years of age.\n* Histologically confirmed unresectable or metastatic melanoma.\n* Subject has no prior systemic treatment for advanced disease.\n* Subject must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).\n* Tumor tissue from site of unresectable or metastatic melanoma must be available for biomarker analyses in order to be randomized.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Subject has had any prior systemic anti-cancer therapy for the treatment of advanced melanoma.\n* Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug.\n* Subject has active central nervous system (CNS) metastases not previously treated.\n* Ocular melanoma.\n* Subject has active or known immune-mediated disorders.\n* Subject has had prior treatment with PD-1/PD-L1 and cytotoxic T lymphocyte- associated protein 4 inhibitors, or other antibodies targeting immune checkpoint pathways.\n* Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of investigational product.\n\nOther protocol-defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": "Key"
}